MYLAN SCORES VICTORY IN PATENT BATTLE

The latest round in the legal battle over the marketing of generic omeprazole delayedrelease capsules has been won by Mylan Laboratories Inc. A district court in New York ruled that Mylan's generic version of Prilosec does not infringe on AstraZeneca's patents for the popular heartburn drug. At the same time, however, the court held that generic omeprazole products made by 2 other companies, Canada's Apotex Inc and Impax Laboratories Inc in California, do infringe on AstraZeneca's patents.